Cytomegalovirus (CMV) Clinical Trials

10 recruiting

Cytomegalovirus (CMV) Trials at a Glance

12 actively recruiting trials for cytomegalovirus (cmv) are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Seoul, Tianjin, and London. Lead sponsors running cytomegalovirus (cmv) studies include Takeda, Western Sydney Local Health District, and IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Browse cytomegalovirus (cmv) trials by phase

Treatments under study

About Cytomegalovirus (CMV) Clinical Trials

Looking for clinical trials for Cytomegalovirus (CMV)? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytomegalovirus (CMV) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytomegalovirus (CMV) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

Kidney Transplant; ComplicationsKidney DiseasesCytomegalovirus (CMV)
University of California, San Francisco360 enrolled5 locationsNCT06798909
Recruiting
Phase 3

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Cytomegalovirus (CMV)
Takeda20 enrolled12 locationsNCT06439342
Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

Kidney DiseaseCytomegalovirus (CMV)Kidney Failure
Takeda10 enrolled25 locationsNCT06243731
Recruiting
Phase 2

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies

Cytomegalovirus (CMV)
Seoul National University Hospital20 enrolled1 locationNCT07014319
Recruiting

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

Cytomegalovirus (CMV)
Takeda168 enrolled1 locationNCT06555432
Recruiting

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Cytomegalovirus (CMV)
Takeda250 enrolled1 locationNCT06577363
Recruiting

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

Cytomegalovirus (CMV)
Takeda75 enrolled9 locationsNCT06677892
Recruiting
Phase 3

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Cytomegalovirus (CMV)
Takeda80 enrolled47 locationsNCT05319353
Recruiting

A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

Cytomegalovirus (CMV)
Takeda10 enrolled1 locationNCT06213974
Recruiting

Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases

Cytomegalovirus (CMV)Inflammatory Bowel Disease (IBD)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled1 locationNCT06793124
Recruiting
Phase 2

A randomised trial of third-party virus-specific T cells in patients with untreated viral infection after an allogeneic stem cell transplantation

Cytomegalovirus (CMV) infection
Western Sydney Local Health District144 enrolled6 locationsACTRN12620000171910
Recruiting
Phase 1

A phase 1 clinical trial of peptide-pulsed monocyte-derived dendritic cell vaccination to expand adoptively transferred cytomegalovirus -specific cytotoxic T lymphocytes after allogeneic stem cell transplantation

Cytomegalovirus (CMV) reactivation and disease
Western Sydney Local Health District18 enrolled1 locationACTRN12608000458336